{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T05:40:14Z","timestamp":1752212414441,"version":"3.41.2"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T00:00:00Z","timestamp":1752192000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>We report a rare hematological immune-related adverse event (irAE) induced by durvalumab, an immune checkpoint inhibitor, after conversion surgery in a patient with intrahepatic cholangiocarcinoma (ICC). A 72-year-old male was admitted for recurrent ICC treatment in the posterior sector. The primary treatment chosen was systemic chemotherapy with durvalumab combined with gemcitabine and cisplatin. After eight cycles of chemotherapy, partial hepatectomy was performed against three nodules of ICC at liver segments 6 and 7 as conversion surgery. Approximately 3 months after the last injection of durvalumab, the patient was readmitted to our department due to a high fever. The number of neutrophils dropped to zero. Despite daily administration of granulocyte colony-stimulating factor, the patient had agranulocytosis with neutrophil counts remaining between 0 and 80\/\u00b5L for 16 days. The results of the bone marrow biopsy indicated that the patient had cytotoxicity due to autoimmunity against the common progenitor cells of granulocytes and monocytes as an adverse reaction to durvalumab. The patient was diagnosed with immune-related neutropenia and started on steroid bolus therapy. Four days after initiating steroid therapy, the neutrophil count began to improve, reaching 1540\/\u00b5L after 7 days, and remained stable thereafter. This case highlights the potential for durvalumab-induced immune-related agranulocytosis following conversion surgery in a patient with ICC, emphasizing the importance of careful monitoring and timely management of irAEs, particularly in the context of postoperative infections.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1610190","type":"journal-article","created":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T05:23:49Z","timestamp":1752211429000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Durvalumab induced immune-related agranulocytosis after conversion surgery in a patient with intrahepatic cholangiocarcinoma: a case report"],"prefix":"10.3389","volume":"16","author":[{"given":"Yoshihito","family":"Kitamura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seiichi","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shintaro","family":"Kuroda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naruhiko","family":"Honmyo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryosuke","family":"Nakano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Tahara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Ohira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kentaro","family":"Ide","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsuyoshi","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuo","family":"Ichinohe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Ohdan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,7,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1097\/cm9.0000000000002759","article-title":"Advances in immunotherapy for biliary tract cancers","volume":"137","author":"Zhao","year":"2024","journal-title":"Chin Med J (Engl)"},{"key":"B2","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/s13046-021-01987-7","article-title":"Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer","volume":"40","author":"Zhang","year":"2021","journal-title":"J Exp Clin Cancer Res"},{"key":"B3","doi-asserted-by":"publisher","first-page":"3993","DOI":"10.3390\/cancers15153993","article-title":"New era of immune-based therapy in intrahepatic cholangiocarcinoma","volume":"15","author":"Kawamura","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B4","doi-asserted-by":"publisher","first-page":"694","DOI":"10.6004\/jnccn.2023.0035","article-title":"NCCN guidelines\u00ae Insights: biliary tract cancers, version 2","volume":"21","author":"Benson","year":"2023","journal-title":"2023. J Natl Compr Canc Netw"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.10.506","article-title":"Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Vogel","year":"2023","journal-title":"Ann Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2200015","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer","volume":"1","author":"Oh","year":"2022","journal-title":"NEJM Evid"},{"key":"B7","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ejca.2019.07.014","article-title":"Haematological immune-related adverse events with immune checkpoint inhibitors, how to manage","volume":"122","author":"Michot","year":"2019","journal-title":"Eur J Cancer"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2021-0131","article-title":"Delayed immune-related neutropenia with hepatitis by pembrolizumab","volume":"14","author":"Nakako","year":"2022","journal-title":"Immunotherapy"},{"key":"B9","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/s40425-019-0648-3","article-title":"Isolated neutropenia as a rare but serious adverse event secondary to immune checkpoint inhibition","volume":"7","author":"Naqash","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.765608","article-title":"Grade 4 neutropenia secondary to immune checkpoint inhibition - A descriptive observational retrospective multicenter analysis","volume":"11","author":"Zaremba","year":"2021","journal-title":"Front Oncol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.3390\/jcm9061808","article-title":"Idiosyncratic drug-induced neutropenia and agranulocytosis in elderly patients","volume":"9","author":"Lorenzo-Villalba","year":"2020","journal-title":"J Clin Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.cllc.2023.08.017","article-title":"Impact of neoadjuvant immune checkpoint inhibitors on surgery and perioperative complications in patients with non-small-cell lung cancer: A systematic review","volume":"24","author":"Takada","year":"2023","journal-title":"Clin Lung Cancer"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.65981","article-title":"Multimodal treatment with nivolumab contributes to long-term survival in a case of unresectable esophagogastric junction neuroendocrine carcinoma","volume":"16","author":"Hanzawa","year":"2024","journal-title":"Cureus"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn441530-20240526-00188","article-title":"Analysis of the efficacy and safety of preoperative programmed death protein-1 inhibitor combined with chemotherapy in immunotherapy-sensitive patients with locally advanced gastric cancer or adenocarcinoma of the esophagogastric junction","volume":"27","author":"Li","year":"2024","journal-title":"Zhonghua Wei Chang Wai Ke Za Zhi"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajt.2024.01.007","article-title":"Atezolizumab plus bevacizumab as a downstaging therapy for liver transplantation in hepatocellular carcinoma with portal vein thrombosis: The first report","volume":"24","author":"Kumar","year":"2024","journal-title":"Am J Transplant"},{"key":"B16","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.3390\/cancers16132387","article-title":"Evolution of systemic treatment for hepatocellular carcinoma: changing treatment strategies and concepts","volume":"16","author":"Moriguchi","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2100070","article-title":"Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","volume":"1","author":"Abou-Alfa","year":"2022","journal-title":"NEJM Evid"},{"key":"B18","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s11912-020-0897-9","article-title":"Immune-related adverse events (irAEs): diagnosis, management, and clinical pearls","volume":"22","author":"Darnell","year":"2020","journal-title":"Curr Oncol Rep"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2020.102134","article-title":"Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors - A systematic review and meta-analysis","volume":"92","author":"Hussaini","year":"2021","journal-title":"Cancer Treat Rev"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-024-05566-9","article-title":"The prevalence of neutropenia and association with infections in patients with systemic lupus erythematosus: a Swedish single-center study conducted over 14 years","volume":"44","author":"Saleh","year":"2024","journal-title":"Rheumatol Int"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1610190\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T05:23:50Z","timestamp":1752211430000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1610190\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,11]]},"references-count":20,"alternative-id":["10.3389\/fimmu.2025.1610190"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1610190","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,11]]},"article-number":"1610190"}}